1. Home
  2. SUI vs JAZZ Comparison

SUI vs JAZZ Comparison

Compare SUI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sun Communities Inc.

SUI

Sun Communities Inc.

N/A

Current Price

$115.33

Market Cap

14.4B

Sector

Real Estate

ML Signal

N/A

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

N/A

Current Price

$229.20

Market Cap

16.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SUI
JAZZ
Founded
1975
2003
Country
United States
Ireland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4B
16.1B
IPO Year
1996
2007

Fundamental Metrics

Financial Performance
Metric
SUI
JAZZ
Price
$115.33
$229.20
Analyst Decision
Buy
Buy
Analyst Count
19
22
Target Price
$135.21
★ $297.50
AVG Volume (30 Days)
★ 1.1M
715.5K
Earning Date
10-26-2026
11-02-2026
Dividend Yield
★ 3.90%
N/A
EPS Growth
★ 1426.76
N/A
EPS
N/A
★ 0.04
Revenue
★ $2,306,100,000.00
$1,618,693,000.00
Revenue This Year
N/A
$12.68
Revenue Next Year
$1.96
$5.34
P/E Ratio
★ N/A
$5,907.78
Revenue Growth
N/A
★ N/A
52 Week Low
$109.77
$156.95
52 Week High
$137.85
$266.38

Technical Indicators

Market Signals
Indicator
SUI
JAZZ
Relative Strength Index (RSI) 45.16 48.42
Support Level $109.86 $222.49
Resistance Level $124.16 $244.93
Average True Range (ATR) 2.64 8.63
MACD -0.48 0.33
Stochastic Oscillator 15.82 36.41

Price Performance

Historical Comparison
SUI
JAZZ

About SUI Sun Communities Inc.

Sun Communities is a residential REIT that focuses on owning manufactured housing and recreational vehicle communities. The company currently owns a portfolio of 455 properties, which includes 295 manufactured housing communities and 160 RV communities. Sun targets owning properties that are desirable as second homes or vacation properties, with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: